8-K
filed May 9, 2023, 7:59 PM ET
ticker DSGN
CIK 0001807120
earnings
confidence high
sentiment positive
materiality 0.55
Design Therapeutics reports Q1 2023 net loss of $19.3M; cash $315.4M; Phase 1 MAD data for DT-216 expected in Q3 2023
Design Therapeutics, Inc.
2023-Q1 EPS reported
-$0.35
- Net loss of $19.3M for Q1 2023; R&D expenses $15.7M, G&A expenses $5.9M.
- Cash, equivalents and marketable securities $315.4M, expected to fund operations through 2025.
- Initial Phase 1 multiple-ascending dose trial data for DT-216 in Friedreich ataxia expected Q3 2023.
- IND submission for DT-168 eye drop for FECD on track for H2 2023; preclinical data presented at ARVO 2023.
- IND submission for DM1 GeneTAC program on track for H2 2024; development candidate selection underway.
Key facts
Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.95
Design Therapeutics, Inc. reported financial results for for the quarter ended March 31, 2023.
- Period
- for the quarter ended March 31, 2023
- Result
- reported results
Exact text from the filing
Research and development (R&D) expenses were $15.7 million for the quarter ended March 31, 2023.
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.95
Design Therapeutics, Inc. reported financial results for for the quarter ended March 31, 2023.
- Period
- for the quarter ended March 31, 2023
- Result
- reported results
Exact text from the filing
General and administrative (G&A) expenses were $5.9 million for the quarter ended March 31, 2023.
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.95
Design Therapeutics, Inc. reported for the three months ended March 31, 2023 results: net income Net loss was $19.3 million for the quarter ended March 31, 2023..
- Period
- for the three months ended March 31, 2023
- Net income
- Net loss was $19.3 million for the quarter ended March 31, 2023.
- Result
- reported results
Exact text from the filing
Net loss was $19.3 million for the quarter ended March 31, 2023.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.